Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.